Telix Pharmaceuticals company profile
Company profile
Telix Pharmaceuticals has 1,120 employees and is headquartered in North Melbourne, Australia.
Telix Pharmaceuticals develops and commercializes radiopharmaceuticals, both therapeutic and diagnostic, and its largest segment is Precision Medicine, built around imaging agents such as Illuccix and Gozellix for prostate cancer. Its pipeline includes the lutetium-labeled radio antibody-drug conjugate TLX591, which is in a Phase 3 trial for advanced prostate cancer, along with candidates for kidney cancer, glioblastoma, soft tissue sarcoma and bone metastases. The company also operates a Therapeutics segment and a Manufacturing Solutions segment, and it serves customers in Australia, Belgium, Canada, the United Kingdom, the United States and other markets, with a strategic collaboration with University Hospital Essen.
Revenue reached USD 803.8 million in the fiscal year ended December 2025, up 55.6% from the previous year, while the company posted a net loss of USD 7.1 million for the same period. Telix had 1,120 employees and is headquartered in North Melbourne, Australia. The company was founded in 2015.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Headquarters
- 55 Flemington Road, 3051, North Melbourne
- Employees
- 1,120
- Chief executive
- Christian Behrenbruch
- Founded
- 2015
- Fiscal year
- January - December
- Listing
- TLX · ASX
- Indices
- S&P/ASX 200
- Currency
- AUD
- ISIN
- AU000000TLX2
- Website
- telixpharma.com
Telix Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Telix PharmaceuticalsTLX | Australia | $2.92B | 1,120 | 6.2% | 92.3 |
| InSilico Medicine Cayman TopCo3696 | Hong Kong SAR China | $2.59B | 333 | -6.9% | — |
| 3SBio1530 | Hong Kong SAR China | $4.56B | 6,068 | 60.3% | 3.90 |
| Neuren PharmaceuticalsNEU | Australia | $1.83B | 8 | 19.9% | 144.0 |
| MesoblastMSB | Australia | $1.48B | 108 | -42.6% | — |
| Akeso9926 | Hong Kong SAR China | $6.81B | 4,082 | -30.7% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
